(19)
(11) EP 3 911 354 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.04.2024 Bulletin 2024/14

(45) Mention of the grant of the patent:
19.07.2023 Bulletin 2023/29

(21) Application number: 20701951.4

(22) Date of filing: 20.01.2020
(51) International Patent Classification (IPC): 
A61K 38/16(2006.01)
C07K 14/00(2006.01)
A61P 27/16(2006.01)
 A61K 48/00(2006.01)
C12N 15/86(2006.01)
(52) Cooperative Patent Classification (CPC):
A01K 67/0275; A01K 67/0276; A01K 2217/056; A01K 2217/075; A01K 2217/20; A01K 2227/105; A01K 2267/0306; A61K 38/16; A61K 48/005; A61P 27/16; C12N 2750/14143; C12N 2750/14144; C07K 14/47
(86) International application number:
PCT/EP2020/051283
(87) International publication number:
WO 2020/148458 (23.07.2020 Gazette 2020/30)

(54)

AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE

AAV-VERMITTELTE GENTHERAPIE ZUR WIEDERHERSTELLUNG DES OTOFERLIN-GENS

THÉRAPIE GÉNIQUE MÉDIÉE PAR AAV RESTAURANT LE GÈNE OTOFERLINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.01.2019 EP 19305071

(43) Date of publication of application:
24.11.2021 Bulletin 2021/47

(60) Divisional application:
23184106.5 / 4295913

(73) Proprietors:
  • Institut Pasteur
    75015 Paris (FR)
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    75016 Paris (FR)
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75013 Paris (FR)

(72) Inventors:
  • SAFIEDDINE, Saaid
    75012 Paris (FR)
  • PETIT, Christine
    75012 Paris (FR)

(74) Representative: Icosa 
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR)


(56) References cited: : 
   
  • HANAN AL-MOYED ET AL: "A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice", EMBO MOLECULAR MEDICINE (ONLINE), vol. 11, no. 1, 1 January 2019 (2019-01-01), page e9396, XP055574125, DE ISSN: 1757-4684, DOI: 10.15252/emmm.201809396
  • AHMED HENA ET AL: "Emerging Gene Therapies for Genetic Hearing Loss", JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY, SPRINGER, NEW YORK, NY, US, vol. 18, no. 5, 16 August 2017 (2017-08-16), pages 649-670, XP036327909, ISSN: 1525-3961, DOI: 10.1007/S10162-017-0634-8 [retrieved on 2017-08-16]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).